Tradeline, Inc. filters and categorizes new-construction and industry news from regional and professional journals across the country. Here you will find new projects, products, and regulatory updates.
Industry News
University of Hawaii Plans Cancer Research Center
The University of Hawaii has initiated the design phase for the $120 million Cancer Research Center of Hawaii in Kakaako. Construction is expected to begin in summer of 2010. The project manager is Kobayashi Group with Skyline Construction as designer and developer. Wilson Okamoto and Associates will provide project planning services. The facility is expected to open in 2013.
Eli Lilly Opens Biotechnology Center
Eli Lilly and Co. opened its new biotechnology center in San Diego in fall of 2009. Located in the 450,000-sf Campus Pointe complex near UC San Diego in La Jolla, the facility will house up to 200 scientists engaged in the research and development of potential medicines. The Lilly Biotechnology Center will also provide space for clinical trials.
Clarian Health Builds Saxony Medical Center
Clarian Health is constructing the $190 million Clarian Saxony Medical Center in Fishers, Ind. The 200,000-sf, 44-bed acute care hospital will provide primary care, surgery, sports medicine, urgent care, and imaging facilities. Completion is expected in late 2011. A 100,000-sf medical office building will also be built at the site.
Louisiana State University Academic Medical Center Selects Jacobs for Program Management
Louisiana State University Academic Medical Center has selected Jacobs Engineering Group to provide program management services for its planned $754 million replacement facility in New Orleans. The 1.6 million-sf project will include a 424-bed hospital, an ambulatory care facility, a central plant, and a 1,350-space parking structure.
CPL Biologicals Breaks Ground on Influenza Vaccine Plant
CPL Biologicals broke ground in fall of 2009 on an influenza vaccine manufacturing facility in Ahmedabad, India. The 25,000-sf building will be operational in the first quarter of 2010. The facility will use virus-like particle (VLP) vaccine technology to produce commercial-scale quantities of VLP-based influenza vaccines. The plant will be able to produce over 60 million doses annually at full capacity. CPL Biologicals is a joint venture of Novavax and Cadila Pharmaceuticals of India.